Back to Journals » OncoTargets and Therapy » Volume 13

RETRACTED ARTICLE: The LINC01260 Functions as a Tumor Suppressor via the miR-562/CYLD/NF-κB Pathway in Non-Small Cell Lung Cancer

Authors Chen Y, Lei Y, Lin J, Huang Y, Zhang J, Chen K, Sun S, Lin X 

Received 24 March 2020

Accepted for publication 11 August 2020

Published 20 October 2020 Volume 2020:13 Pages 10707—10719

DOI https://doi.org/10.2147/OTT.S253730

Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 3

Editor who approved publication: Dr Sanjay Singh



This paper has been retracted.

Chen Y, Lei Y, Lin J, et al. Onco Targets Ther. 2020;13:10707-10719.

At the author’s request, we, the Editors and Publisher of OncoTargets and Therapy have retracted the following article.

Following publication of the article, concerns were raised about the duplication of images from Figures 2, 4 and 7 with images from other unrelated articles. Specifically,

  • Images for Figure 2D have been duplicated with images for Figure 2F from Luo J, Jin Y, Li M, Dong L. Tumor suppressor miR‑613 induces cisplatin sensitivity in non‑small cell lung cancer cells by targeting GJA1. Molecular Medicine Reports. 2021;23:385. https://doi.org/10.3892/mmr.2021.12024.
  • The images for Figure 4A, sh-LINC01260 and sh-Control have been duplicated with the images for Figure 3A, NC and miR-613 mimics, respectively, from Luo et al, 2021.
  • Images for Figure 4F have been duplicated with images for Figure 1D from Xu L, Zhang B, Li W. Downregulated expression levels of USP46 promote the resistance of ovarian cancer to cisplatin and are regulated by PUM2. Molecular Medicine Reports. 2021;23:263. https://doi.org/10.3892/mmr.2021.11902; Figure 3F from Zhang X, Lian T, Fan W, et al. Long-Noncoding RNA CASC9 Promotes Progression of Non-Small Cell Lung Cancer by Promoting the Expression of CDC6 Through Binding to HuR. Cancer Manag Res. 2020;12:9033-9043. https://doi.org/10.2147/CMAR.S268375; Figure 7d from Qu Z, Li S. Long noncoding RNA LINC01278 favors the progression of osteosarcoma via modulating miR-133a-3p/PTHR1 signaling. J Cell Physiol. 2020;1–13. https://doi.org/10.1002/jcp.29582 and Figure 7F from Zhang RL, Aimudula A, Dai JH, Bao YX. RASA1 inhibits the progression of renal cell carcinoma by decreasing the expression of miR-223-3p and promoting the expression of FBXW7. Biosci Rep. 2020;40(7):BSR20194143. doi: https://doi.org/10.1042/BSR20194143.
  • The image for Figure 4G, PCNA, sh-LINC01260 has been duplicated with the image 3E, Ki-67, NC from Luo et al, 2021.
  • Images for Figure 7F have been duplicated with images for Figure 1e from Liu S, Liu LH, Hu WW, Wang M. Long noncoding RNA TUG1 regulates the development of oral squamous cell carcinoma through sponging miR-524-5p to mediate DLX1 expression as a competitive endogenous RNA. J Cell Physiol. 2019;234:20206–20216. https://doi.org/10.1002/jcp.28620 and Figure 2D and 2H from Xing T, Chen P, Wu J, et al. UPF1 Participates in the Progression of Endometrial Cancer by Inhibiting the Expression of lncRNA PVT1. Onco Targets Ther. 2020;13:2103-2114. https://doi.org/10.2147/OTT.S233149.

The authors explained that a third party had carried out the experiments and there had been an equipment malfunction. However, it was not made clear how this subsequently led to the duplication of several images across multiple, unrelated articles. In addition, the authors were unable to provide original data for the study. As verifying the validity of published work is core to the integrity of the scholarly record, the authors requested to retract the article and the Editor and Publisher agreed with this decision.

We have been informed in our decision-making by our editorial policies and COPE guidelines.

The retracted article will remain online to maintain the scholarly record, but it will be digitally watermarked on each page as ‘Retracted’.

Creative Commons License © 2020 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.